ADMA Biologics, Inc.ADMANASDAQ
Loading
Gross Profit Growth AcceleratingAccelerating
Percentile Rank54
3Y CAGR-28.0%
Year-over-Year Change
Year-over-year gross profit growth rate
3Y CAGR
-28.0%/yr
vs -16.0%/yr prior
Acceleration
-12.1pp
Decelerating
Percentile
P54
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.44% |
| Q3 2025 | 12.49% |
| Q2 2025 | 10.03% |
| Q1 2025 | -3.53% |
| Q4 2024 | 6.16% |
| Q3 2024 | 3.84% |
| Q2 2024 | 46.91% |
| Q1 2024 | 25.80% |
| Q4 2023 | 26.10% |
| Q3 2023 | 47.71% |
| Q2 2023 | 1.07% |
| Q1 2023 | 16.48% |
| Q4 2022 | 46.81% |
| Q3 2022 | 24.29% |
| Q2 2022 | 112.16% |
| Q1 2022 | 4.29% |
| Q4 2021 | 811.28% |
| Q3 2021 | 138.46% |
| Q2 2021 | 41.79% |
| Q1 2021 | 66.61% |
| Q4 2020 | -226.45% |
| Q3 2020 | 72.34% |
| Q2 2020 | 13.90% |
| Q1 2020 | -2019.11% |
| Q4 2019 | 149.80% |
| Q3 2019 | 82.35% |
| Q2 2019 | 33.12% |
| Q1 2019 | 17.06% |
| Q4 2018 | -43.62% |
| Q3 2018 | 1.11% |
| Q2 2018 | 39.16% |
| Q1 2018 | -10353.75% |
| Q4 2017 | 101.22% |
| Q3 2017 | -602.07% |
| Q2 2017 | -192.30% |
| Q1 2017 | -22.89% |
| Q4 2016 | 9.24% |
| Q3 2016 | 29.61% |
| Q2 2016 | 8.17% |
| Q1 2016 | -15.06% |